S&P 500   4,059.74 (+1.29%)
DOW   32,474.40 (+0.78%)
QQQ   304.41 (+2.00%)
AAPL   148.45 (+2.00%)
MSFT   264.31 (+1.07%)
FB   201.49 (+0.72%)
GOOGL   2,315.60 (+1.17%)
AMZN   2,260.90 (+2.02%)
TSLA   754.36 (+4.14%)
NVDA   179.64 (+4.05%)
BABA   90.75 (+4.94%)
NIO   16.54 (+13.68%)
AMD   102.10 (+8.34%)
CGC   5.89 (+2.79%)
MU   73.68 (+4.56%)
T   20.47 (+0.94%)
GE   76.38 (+2.34%)
F   13.39 (+2.61%)
DIS   107.62 (+2.32%)
AMC   12.41 (+5.98%)
PFE   51.07 (+0.79%)
PYPL   78.71 (+1.37%)
NFLX   189.08 (+1.38%)
S&P 500   4,059.74 (+1.29%)
DOW   32,474.40 (+0.78%)
QQQ   304.41 (+2.00%)
AAPL   148.45 (+2.00%)
MSFT   264.31 (+1.07%)
FB   201.49 (+0.72%)
GOOGL   2,315.60 (+1.17%)
AMZN   2,260.90 (+2.02%)
TSLA   754.36 (+4.14%)
NVDA   179.64 (+4.05%)
BABA   90.75 (+4.94%)
NIO   16.54 (+13.68%)
AMD   102.10 (+8.34%)
CGC   5.89 (+2.79%)
MU   73.68 (+4.56%)
T   20.47 (+0.94%)
GE   76.38 (+2.34%)
F   13.39 (+2.61%)
DIS   107.62 (+2.32%)
AMC   12.41 (+5.98%)
PFE   51.07 (+0.79%)
PYPL   78.71 (+1.37%)
NFLX   189.08 (+1.38%)
S&P 500   4,059.74 (+1.29%)
DOW   32,474.40 (+0.78%)
QQQ   304.41 (+2.00%)
AAPL   148.45 (+2.00%)
MSFT   264.31 (+1.07%)
FB   201.49 (+0.72%)
GOOGL   2,315.60 (+1.17%)
AMZN   2,260.90 (+2.02%)
TSLA   754.36 (+4.14%)
NVDA   179.64 (+4.05%)
BABA   90.75 (+4.94%)
NIO   16.54 (+13.68%)
AMD   102.10 (+8.34%)
CGC   5.89 (+2.79%)
MU   73.68 (+4.56%)
T   20.47 (+0.94%)
GE   76.38 (+2.34%)
F   13.39 (+2.61%)
DIS   107.62 (+2.32%)
AMC   12.41 (+5.98%)
PFE   51.07 (+0.79%)
PYPL   78.71 (+1.37%)
NFLX   189.08 (+1.38%)
S&P 500   4,059.74 (+1.29%)
DOW   32,474.40 (+0.78%)
QQQ   304.41 (+2.00%)
AAPL   148.45 (+2.00%)
MSFT   264.31 (+1.07%)
FB   201.49 (+0.72%)
GOOGL   2,315.60 (+1.17%)
AMZN   2,260.90 (+2.02%)
TSLA   754.36 (+4.14%)
NVDA   179.64 (+4.05%)
BABA   90.75 (+4.94%)
NIO   16.54 (+13.68%)
AMD   102.10 (+8.34%)
CGC   5.89 (+2.79%)
MU   73.68 (+4.56%)
T   20.47 (+0.94%)
GE   76.38 (+2.34%)
F   13.39 (+2.61%)
DIS   107.62 (+2.32%)
AMC   12.41 (+5.98%)
PFE   51.07 (+0.79%)
PYPL   78.71 (+1.37%)
NFLX   189.08 (+1.38%)
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Forecast, Price & News

$0.90
+0.04 (+4.84%)
(As of 05/17/2022 02:03 PM ET)
Add
Compare
Today's Range
$0.88
$0.96
50-Day Range
$0.80
$1.50
52-Week Range
$0.79
$4.49
Volume
16,632 shs
Average Volume
711,986 shs
Market Capitalization
$96.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.27
30 days | 90 days | 365 days | Advanced Chart
Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

Fortress Biotech logo

About Fortress Biotech

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
Employees
173
Year Founded
N/A

Sales & Book Value

Annual Sales
$68.79 million
Book Value
$2.27 per share

Profitability

Net Income
$-64.70 million
Pretax Margin
-231.44%

Debt

Price-To-Earnings

Miscellaneous

Free Float
79,163,000
Market Cap
$96.84 million
Optionable
Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/17/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.19 out of 5 stars

Medical Sector

376th out of 1,423 stocks

Pharmaceutical Preparations Industry

150th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -













Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

Is Fortress Biotech a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fortress Biotech stock.
View analyst ratings for Fortress Biotech
or view top-rated stocks.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 2,620,000 shares, an increase of 42.4% from the April 15th total of 1,840,000 shares. Based on an average daily volume of 593,700 shares, the short-interest ratio is currently 4.4 days. Currently, 3.1% of the company's shares are short sold.
View Fortress Biotech's Short Interest
.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Fortress Biotech
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) issued its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.10. Fortress Biotech had a negative net margin of 88.31% and a negative trailing twelve-month return on equity of 32.56%. During the same period in the previous year, the company earned ($0.11) earnings per share.
View Fortress Biotech's earnings history
.

What price target have analysts set for FBIO?

5 brokerages have issued 1-year target prices for Fortress Biotech's stock. Their forecasts range from $6.00 to $20.00. On average, they anticipate Fortress Biotech's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,120.1% from the stock's current price.
View analysts' price targets for Fortress Biotech
or view top-rated stocks among Wall Street analysts.

Who are Fortress Biotech's key executives?
Fortress Biotech's management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 67, Pay $576.65k)
  • Mr. Michael S. Weiss Esq., Vice Chairman & Exec. Vice Chairman of Strategic Devel. (Age 56, Pay $576.63k)
  • Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 60, Pay $583.11k)
  • Dr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 68, Pay $386.5k)
  • Dr. Thomas F. Schaible, Project Leader of Inflammatory Bowel Disease
What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (8.26%), Vanguard Group Inc. (5.30%), BlackRock Inc. (4.40%), State Street Corp (1.21%), Renaissance Technologies LLC (1.03%) and Northern Trust Corp (0.62%). Company insiders that own Fortress Biotech stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends for Fortress Biotech
.

Which major investors are selling Fortress Biotech stock?

FBIO stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, BlackRock Inc., Northern Trust Corp, Group One Trading L.P., HAP Trading LLC, Vanguard Group Inc., Kestra Advisory Services LLC, and Cutler Group LP.
View insider buying and selling activity for Fortress Biotech
or view top insider-selling stocks.

Which major investors are buying Fortress Biotech stock?

FBIO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, GSA Capital Partners LLP, State Street Corp, National Asset Management Inc., Envestnet Asset Management Inc., Goldman Sachs Group Inc., and Charles Schwab Investment Management Inc.. Company insiders that have bought Fortress Biotech stock in the last two years include Lindsay A Md Rosenwald, and Malcolm Hoenlein.
View insider buying and selling activity for Fortress Biotech
or or view top insider-buying stocks.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $0.90.

How much money does Fortress Biotech make?

Fortress Biotech has a market capitalization of $96.84 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64.70 million in net income (profit) each year or ($0.860010) on an earnings per share basis.

How many employees does Fortress Biotech have?

Fortress Biotech employs 173 workers across the globe.

What is Fortress Biotech's official website?

The official website for Fortress Biotech is www.fortressbiotech.com.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at [email protected], or via fax at 781-652-4545.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.